CareDx, Inc. (CDNA) Market Cap & Valuation Ratios
CareDx, Inc. (CDNA) has a market cap of $3.6B, a trailing P/E of 33.4 and a price-to-sales ratio of 7.8, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CDNACareDx, Inc.Follow CDNA — free
—
Price chart with a free account
- Market cap
- 3.6B
- P/E TTM
- 33.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
diagnostics & research · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CDNA | 3.6 | 33.4 | 7.0 | 26.2 | 1.0% | +34% | 24% | 67% |
| TWST | 8.8 | — | 20.0 | — | -1.1% | +19% | -34% | -42% |
| GRAL | 5.9 | — | 35.5 | — | -5.0% | +23% | -338% | -24% |
| RDNT | 5.5 | — | 2.7 | 25.4 | 1.3% | +19% | 3% | 3% |
| SHC | 5.2 | 31.8 | 5.7 | 13.0 | 2.2% | +8% | 34% | 10% |
| BLLN | 5.1 | 193.9 | 11.6 | 92.1 | 0.7% | +90% | 11% | 54% |
| ADPT | 4.1 | — | 13.2 | — | -0.6% | +50% | -12% | -13% |
| VCYT | 3.9 | 34.2 | 6.3 | 28.1 | 4.3% | +17% | 19% | 10% |
| NEO | 2.1 | — | 3.1 | — | -0.3% | +11% | -9% | -7% |
| PSNL | 1.7 | — | 21.2 | — | -6.0% | -13% | -164% | -82% |
| WGS | 1.7 | — | 3.6 | — | -4.5% | +25% | -20% | -35% |
| Median of these 10 | 34.2 | 9.0 | 26.7 | -0.5% | +19% | -11% | -10% |
P/E 33.4 vs. a peer median of 34.2; EV/Sales 7.0 vs. 9.0.
Growth vs. price
each dot a company · hover or tap for valuesTWST and GRAL and RDNT and ADPT and NEO and PSNL and WGS have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
CareDx, Inc. — questions
- What is CareDx, Inc.'s market cap?
- $3.6B.
- What is CareDx, Inc.'s P/E ratio?
- 33.4 on trailing twelve-month earnings to 2026-06-30.
- What is CareDx, Inc.'s price-to-sales ratio?
- 7.8.
Every figure on this page comes from CareDx, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.